Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated. Among 25,531 participants in the National Health and Nutrition Examination Survey (NHANES) from 2015 to.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule inhibitor that prevents the.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Secondhand permanent pacemaker use in poorer countries, following thorough cleaning and repackaging, has not resulted in patient harm so far, according to the My Heart Your Heart trialists. In patients who could.
Nature Reviews - Cardiology
NOVEMBER 18, 2024
Nature Reviews Cardiology, Published online: 19 November 2024; doi:10.1038/s41569-024-01105-y Large language models represent a transformative leap in artificial intelligence and natural language processing, offering exciting potential across cardiology, from clinical care to education and research. However, several crucial challenges limit the practical implementation of large language models in cardiology.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Electronic nudges increased uptake of flu vaccines among patients with a history of acute myocardial infarction (MI), results from three Danish randomized trials showed. Among over 2 million patients, a letter explaining.
HCPLive
NOVEMBER 18, 2024
Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.
Science Daily - Heart Disease
NOVEMBER 18, 2024
A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in healthy adults in comparison to the oral and intravenous forms of the medication. The existing oral and intravenous forms of bumetanide are commonly prescribed for people with heart failure because they ease tissue swelling, a common cause of symptoms for people with heart failure.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
NOVEMBER 18, 2024
In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.
American College of Cardiology
NOVEMBER 18, 2024
What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
Becker's Hospital Review - Cardiology
NOVEMBER 18, 2024
Between 2008 and 2019, the share of cardiologists practicing in a hospital, as opposed to an independent practice, increased from 26% to 63%, according to a study published Nov. 15 in the Journal of the American College of Cardiology.
DAIC
NOVEMBER 18, 2024
tim.hodson Mon, 11/18/2024 - 10:55 Nov. 16, 2024 Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific Sessions from its AZALEA-TIMI 71 study that demonstrated the novel factor XI inhibitor abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, as compared to rivaroxaban.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much about increased cardiovascular risk -- if they're taking statins, research presented here suggested.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in healthy adults in comparison to the.
Science Daily - Heart Disease
NOVEMBER 18, 2024
A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to recent research.
HCPLive
NOVEMBER 18, 2024
Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.
Science Daily - Heart Disease
NOVEMBER 18, 2024
Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining how industrially produced trans-unsaturated fatty acids in our food significantly promote ASCVD and encouraging lawmakers to impose regulations on the use of these fats in food.
HCPLive
NOVEMBER 18, 2024
In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.
American College of Cardiology
NOVEMBER 18, 2024
Sacubitril/valsartan was associated with a lower risk cardiotoxicity compared with placebo among high-risk cancer patients being treated with anthracycline (ATN) chemotherapy agents.
HCPLive
NOVEMBER 18, 2024
Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.
Cardiovascular Diabetology
NOVEMBER 18, 2024
The article by Wang et al. titled “Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis” demonst.
DAIC
NOVEMBER 18, 2024
tim.hodson Mon, 11/18/2024 - 15:10 Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented at the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA
Cardiovascular Diabetology
NOVEMBER 18, 2024
Both insulin resistance and hyperglycemia are important risk factors for atherosclerosis. While the characteristics of atherosclerosis are obviously different according to established diabetes, little has been.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR.
Cardiovascular Diabetology
NOVEMBER 18, 2024
Individuals with type 1 diabetes are at increased risk of accelerated atherosclerosis, causing coronary artery disease (CAD). The underlying mechanisms remain unclear, but new theories proposed are damage of g.
Becker's Hospital Review - Cardiology
NOVEMBER 18, 2024
Coronary artery calcium scores can accurately assess cardiovascular risk for both men and women, according to a study presented at the American Heart Association's annual Scientific Sessions Nov. 18.
HCPLive
NOVEMBER 18, 2024
Panelists discuss their clinical experiences with Janus kinase (JAK) inhibitors for treating alopecia, noting observed differences in outcomes and tolerability among various systemic JAK inhibitors, while highlighting the advantages of these therapies over traditional local and systemic treatment options.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or stabilize the structure and function of the heart over a period of 24 to 54 months without major safety.
HCPLive
NOVEMBER 18, 2024
Panelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and heada
Becker's Hospital Review - Cardiology
NOVEMBER 18, 2024
The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The New England Journal of Medicine and presented at the American Heart Association's annual Scientific Sessions.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A clinical trial with adults who have atrial fibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the randomized OPTION trial showed.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline chemotherapy agents. The risk.
HCPLive
NOVEMBER 18, 2024
Panelists discuss key updates in clinical guidelines for chronic kidney disease (CKD) testing in patients with type 2 diabetes, highlighting the latest recommendations for improving screening and diagnosis.
American College of Cardiology
NOVEMBER 18, 2024
Myeloperoxidase inhibition with mitiperstat in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF, respectively) was safe and well-tolerated, but did not improve symptoms or exercise function.
HCPLive
NOVEMBER 18, 2024
Panelists discuss the current barriers to urine albumin-creatinine ratio (uACR) testing, strategies to address these barriers, the guideline goals for reducing uACR, and the importance of a multimodal approach, as well as how increased awareness of chronic kidney disease (CKD) testing can improve patient outcomes and engage health care providers in promoting testing.
American College of Cardiology
NOVEMBER 18, 2024
In this episode, Drs. Newton Wiggins, Stanley Lui, and Sandra Lewis discuss the importance of finances and how aligning your financial situation with your values can foster career flexibility and improve clinician well-being.
HCPLive
NOVEMBER 18, 2024
Orly Vardeny, PharmD, MS, discusses the management and monitoring of hyperkalemia among patients with heart failure with preserved ejection fraction using finerenone.
Expert insights. Personalized for you.
119 
Let's personalize your content